Mannatech (NASDAQ:MTEX – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.
Volatility and Risk
Mannatech has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
Valuation & Earnings
This table compares Mannatech and BeOne Medicines”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mannatech | $117.87 million | 0.12 | $2.49 million | ($0.86) | -8.93 |
| BeOne Medicines | $3.81 billion | 9.72 | -$644.79 million | $0.51 | 662.33 |
Mannatech has higher earnings, but lower revenue than BeOne Medicines. Mannatech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
13.0% of Mannatech shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Mannatech and BeOne Medicines, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
| BeOne Medicines | 1 | 1 | 13 | 0 | 2.80 |
BeOne Medicines has a consensus target price of $378.43, suggesting a potential upside of 12.03%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Mannatech.
Profitability
This table compares Mannatech and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mannatech | -1.50% | -22.75% | -4.75% |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
Summary
BeOne Medicines beats Mannatech on 11 of the 14 factors compared between the two stocks.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.
